The dysregulation of non-coding RNAs (ncRNAs), specifically microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs), leads to the development and advancement of multiple …

Multiple myeloma (MM) is a hematologic neoplasm of plasma cells that is currently deemed
incurable. Despite the introduction of novel immunomodulators and proteasome inhibitors …

Multiple myeloma (MM) is characterized by multiple relapse and, despite the introduction of
novel therapies, the disease becomes ultimately drug-resistant. The tumor …

This two-part review aims to present a current and comprehensive understanding of the
diagnosis and management of plasmablastic lymphoma. The first section, as presented in …

G-protein-coupled receptor class 5 member D (GPRC5D) is detected in malignant plasma
cells in approximately 90% of patients diagnosed with multiple myeloma (MM). Here, we …

Proton pump inhibitors (PPIs) are commonly used in cancer patients, but their impact on
treatment outcomes in multiple myeloma (MM) patients remains unclear. This study …

Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of
patients with advanced non–small cell lung cancer without driver genetic alterations. Most of …

Background In preclinical models, combining a GLUT4 inhibitor with an oxidative
phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma …

Multiple myeloma (MM) is a hematological cancer characterized by abnormal proliferation of
plasma cells in bone marrow. In recent years, autologous stem cell transplantation (ASCT) …

Simple Summary On rare occasions, a handful of innovative cancer drugs may successfully
go through clinical trials and manage to obtain simultaneous regulatory approvals to treat a …